Internal Medicine, Gastroenterology · Santa Fe, NM
NPI
1285993501
Since 2012
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1691 Galisteo St Ste C
Santa Fe, NM, 87505
Phone (915) 329-6542
Groups this clinician bills Medicare through
Medicare paid, 2024
$110K
1,213 services
Medicare patients, 2024
565
Average age 74
Drug cost, 2024
$32K
1,151 prescriptions
Company payments, 2025
$1,151
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel E Bujanda was code 45385 (colonoscopy - lesion removal), 214 times for 214 patients. In total Daniel E Bujanda billed 1,213 services in 43 codes, and Medicare paid $110K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 45385 Colonoscopy - Lesion Removal | Facility | 214 | 214 | $211.75 | $45K |
| 43235 Upper GI Endoscopy | Facility | 113 | 110 | $84.59 | $9,558 |
| 43239 Upper GI Endoscopy | Facility | 109 | 106 | $83.29 | $9,079 |
| G0500 Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 95 | 95 | $4.51 | $429 |
| 45380 Lower GI Endoscopy - Other | Facility | 50 | 49 | $90.23 | $4,512 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 48 | 48 | $176.87 | $8,490 |
| 43450 Digestive/Gastrointestinal | Facility | 46 | 44 | $29.80 | $1,371 |
| 99153 Anesthesia | Facility | 33 | 31 | $9.37 | $309 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 31 | 31 | $173.95 | $5,392 |
| 99204 Office E&M - New | Office | 27 | 27 | $120.52 | $3,254 |
| 45378 Lower GI Endoscopy - Other | Facility | 21 | 21 | $126.56 | $2,658 |
By year: 2022 $110K for 973 services; 2023 $99K for 833 services; 2024 $110K for 1,213 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel E Bujanda prescribed most often to Medicare patients was Peg 3350-Electrolyte (Sodium Chloride/Nahco3/Kcl/Peg), with 466 prescriptions and refills. In total Daniel E Bujanda wrote 1,151 Medicare prescriptions that cost $32K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | 466 | 466 | 448 | $12K |
| Omeprazole Generic | 285 | 776 | 140 | $5,626 |
| Pantoprazole Sodium Generic | 184 | 501 | 77 | $3,074 |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 43 | 43 | 43 | $823 |
| Carvedilol Generic | 25 | 75 | 15 | $227 |
| Esomeprazole Magnesium Generic | 19 | 33 | Under 11 | $334 |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | 19 | 19 | 18 | $299 |
| Gavilyte-N Sodium Chloride/Nahco3/Kcl/Peg | 14 | 14 | 14 | $266 |
Brand drugs: 179 claims; generic drugs: 972 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel E Bujanda $1,151 ($1,151 in general payments such as food, travel and fees) from 12 companies. The largest payer was Janssen Biotech, Inc. with $296.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 7 | $296 |
| Abbvie Inc. ABBV | 19 | $261 |
| Pfizer Inc. PFE | 4 | $156 |
| Ardelyx, Inc. ARDX | 4 | $104 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 3 | $60.83 |
| Medtronic, Inc. MDT | 1 | $59.56 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $52.46 |
| Madrigal Pharmaceuticals MDGL | 2 | $49.81 |
| Genzyme Corporation SNY | 2 | $47.08 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 1 | $26.98 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.